Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abiomed Inc Reaffirms FY 2014 Revenue Guidance


Thursday, 1 Aug 2013 07:02am EDT 

Abiomed Inc maintained its fiscal 2014 revenue guidance in a range of $180 million to $185 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $184 million for fiscal 2014. 

Company Quote

35.49
-0.01 -0.03%
25 Nov 2014